Medical device firm Insulet has enrolled first patient in the clinical trial, which will evaluate the Omnipod Horizon automated glucose control system.
The study will assess the use of a personal model predictive control algorithm with the Omnipod platform in 20 adults with type 1 diabetes.
Insulet is carrying out the trial in a clinical research center setting to generate data that will be used to develop the algorithm.
Omnipod Horizon is an integrated system that combines an on-body tubeless pump, Dexcom continuous glucose monitoring (CGM) technology, modified version of Insulet's handheld controller and modern security system architecture.
Omnipod insulin management system includes two components, comprising of pod and personal diabetes manager (PDM).
Pod, which is designed to store and deliver insulin, can be worn in multiple locations such as abdomen, hip, back of upper arm and upper thigh or lower back.
PDM will wirelessly program the user's personalized insulin delivery and calculate suggested doses and insulin on board.
Insulet president and CEO Patrick Sullivan said: "Our new Omnipod Horizon System is designed to deliver not only improved clinical outcomes, but the greatly desired improvement in quality of life for those living with insulin-dependent diabetes.
"With the first clinical study of our innovative artificial pancreas underway, we have taken another important step in fulfilling our mission to improve the lives of people with diabetes."